In terms of clinical outcome, DLBCL with MYC R (herein after designated as MYC+) has a decreased survival compared to other chromosome aberrations or those lacking a MYC R (herein after designated as MYC−); these cases may require more aggressive therapeutic regimens than the rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R‐CHOP) [1, 7–12]. Here, DDIT3 is linked to diffuse large B-cell lymphoma.